22157.jpg
Soft Tissue Sarcoma Competitive Landscape Analysis 2024: 361 Molecules in the Pipeline, Including 10 Drugs in the Late-stage Pipeline with Roche, BMS, Novartis, and Boehringer Ingelheim Leading
31 juil. 2024 10h50 HE | Research and Markets
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Soft Tissue Sarcoma: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This report provides a data-driven...
Logo.png
Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme, Ipsen, GlaxoSmithKline, Salarius, Merck, Agenus, Mirati
03 août 2023 13h00 HE | DelveInsight Business Research LLP
New York, USA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme,...
22157.jpg
Europe Soft Tissue Sarcoma Market Report 2023: Growing Focus on Personalized Medicine Presents Opportunities
31 mai 2023 05h38 HE | Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type, By End...
Roots-Analysis-Logo.png
The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030, growing at an annualized rate of 27.54% during the period 2021-2030, claims Roots Analysis
22 sept. 2021 09h00 HE | Roots Analysis
London, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Soft Tissue Sarcoma Market: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report...